2023版ESMO临床实践指南:早期乳腺癌的诊断、治疗与随访(上篇) 在2023年12月13日,备受瞩目的《肿瘤学年鉴》(Annals of Oncology,影响因子:50.5)期刊在线发布了2023版ESMO早期乳腺癌临床实践指南——“Early breast cancer: ESMO Clinical Practic...
参考文献: [1]P. Torres-Mozas, F. Galvez Montosa, N. Luque Caro, et al. Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis. 2023 ESMO abstracts. 153P [2]D. Netto, X. Wang, B. Barnes, et al. Correlation between chemoth...
1.ESMO Metastatic Breast Cancer Living Guideline; V1.1; May 2023. 2.Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan ...
for Previously Treated ERBB2(HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases:Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.JAMA Oncol.2023 Feb 1;9(2):197-205.
2023年欧洲肿瘤内科学会乳腺癌大会(ESMO BREAST CANCER 2023)已于2023年5月11日至13日在德国柏林举办,致力于推进科学,传播教育,和改善全球乳腺癌专家的实践。今年的重点是整合转化研究以促进创新的临床实践。 欧洲肿瘤内科学会(ESMO)是医学肿瘤学领域领先的专业组织。ESMO拥有来自全球160多个国家的25,000 多名代表肿...
Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011 长期居住和工作环境对空气污染的暴露与乳腺癌风险:一项嵌套在法国E3N队列研究中的病例对照研究,时间跨度为1990年至2011年 ...
Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011 长期居住和工作环境对空气污染的暴露与乳腺癌风险:一项嵌套在法国E3N队列研究中的病例对照研究,时间跨度为1990年至2011年 ...
[1]P. Torres-Mozas, F. Galvez Montosa, N. Luque Caro, et al. Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis. 2023 ESMO abstracts. 153P [2]D. Netto, X. Wang, B. Barnes, et al. Correlation between chemotherapy respon...
由欧洲肿瘤内科学会(ESMO)主办的2023 ESMO年会将于2023年10月20-24日在西班牙马德里召开。目前,大会常规摘要内容已全部更新,“2023ESMO年会中国医学论坛报学术联播”将持续整理大会重点研究,与大家一起E览盛会! 大会“BREAST CANCER,METASTATIC”领域共设一个优选论文专场与一个简短口头报告专场,汇集转移性乳腺癌治疗最...
1. ESMO Metastatic Breast Cancer Living Guideline; V1.1; May 2023. 2. Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Ja...